iBio (IBIO) Total Assets : $24.52 Mil (As of Sep. 2024)

View and export this data going back to 2008. Start your Free Trial

What is iBio Total Assets?

iBio's Total Assets for the quarter that ended in Sep. 2024 was $24.52 Mil.

During the past 12 months, iBio's average Total Assets Growth Rate was -62.80% per year. During the past 3 years, the average Total Assets Growth Rate was -33.80% per year. During the past 5 years, the average Total Assets Growth Rate was -7.80% per year. During the past 10 years, the average Total Assets Growth Rate was 22.30% per year.

During the past 13 years, iBio's highest 3-Year average Total Assets Growth Rate was 112.60%. The lowest was -33.80%. And the median was 7.10%.

Total Assets is connected with ROA %. iBio's annualized ROA % for the quarter that ended in Sep. 2024 was -59.93%. Total Assets is also linked to Revenue through Asset Turnover. iBio's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

iBio Total Assets Historical Data

The historical data trend for iBio's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio Total Assets Chart

iBio Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Assets

Get a 7-Day Free Trial

94.19

146.97

99.41

41.21

28.73

iBio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															37.68	34.02	50.15	28.73	24.52

iBio Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

iBio's Total Assets for the fiscal year that ended in Jun. 2024 is calculated as

Total Assets	=	Total Equity (A: Jun. 2024 )	+	Total Liabilities (A: Jun. 2024 )
	=	21.324	+	7.41
	=	28.73

iBio's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	17.754	+	6.763
	=	24.52

iBio (AMEX:IBIO) Total Assets Explanation

Total Assets is connected with ROA %.

iBio's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-15.956	/	( (28.734	+	24.517)	/ 2 )
	=	-15.956	/	26.6255
	=	-59.93 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

iBio's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	0	/	( (28.734	+	24.517)	/ 2 )
=	0	/	26.6255
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

iBio Total Assets Related Terms

Thank you for viewing the detailed overview of iBio's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

iBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (AMEX:IBIO) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.ibioinc.com

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Executives

Martin Brenner	officer: Chief Scientific Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Felipe Duran	officer: Interim CFO	8800 HSC PARKWAY, BRYAN TX 77807
William D Clark	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Evert B. Schimmelpennink	director	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd	director, officer: CEO and Executive Chairman	C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz	officer: See Remarks	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux	officer: Chief Operating Officer	2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova	director	RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Gary Sender	director	C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Linda Washington Armstrong	director	8800 HSC PARKWAY, BRYAN TX 77807
John Delta	officer: Principal Accounting Officer	8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd	10 percent owner	10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin	officer: President	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney	officer: Chief Financial Officer	C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis	10 percent owner	C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431